Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANN DOAN-DO BASS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1104925171
CMS profile
50765
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$142,969.68

289 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANN DOAN-DO BASS

NPI 1104925171 · CMS profile ID 50765

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104925171?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANN DOAN-DO BASS, NPI 1104925171, CMS profile ID 50765. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104925171?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ANN DOAN-DO BASS, NPI 1104925171, CMS profile ID 50765. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104925171?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ANN DOAN-DO BASS, NPI 1104925171, CMS profile ID 50765, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1104925171?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

289 matching records · $142,969.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 289 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 289.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ACADIA Pharmaceuticals Inc $17.6408/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837990209 CMS
Biogen, Inc. $1,152.0008/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825593 CMS
Genentech USA, Inc. $2,530.0008/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888963 CMS
Genentech USA, Inc. $124.9908/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888965 CMS
Supernus Pharmaceuticals, Inc. $17.3508/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845004263 CMS
Novartis Pharmaceuticals Corporation $33.2308/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602591 CMS
Novartis Pharmaceuticals Corporation $23.4908/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602619 CMS
AbbVie Inc. $4.8508/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794003267 CMS
CSL Behring $14.7208/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820294575 CMS
Adamas Pharmaceuticals, Inc. $21.2108/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834395503 CMS
Mallinckrodt Hospital Products Inc. $3,430.0008/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845345831 CMS
Mallinckrodt Hospital Products Inc. $108.2308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845345829 CMS
Neurocrine Biosciences, Inc. $29.6008/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837782441 CMS
GENZYME CORPORATION $14.4208/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843494443 CMS
Genentech USA, Inc. $24.7808/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888969 CMS
LivaNova USA, Inc. $22.3608/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844254035 CMS
Amgen Inc. $14.3708/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825147419 CMS
Alexion Pharmaceuticals, Inc. $420.0007/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783123253 CMS
GENZYME CORPORATION $1,911.0007/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843494445 CMS
AbbVie Inc. $29.3607/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794003263 CMS
GENZYME CORPORATION $1,911.0007/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843494447 CMS
Novartis Pharmaceuticals Corporation $2,527.0007/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602575 CMS
Alexion Pharmaceuticals, Inc. $24.8507/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783123225 CMS
Novartis Pharmaceuticals Corporation $1.3807/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602615 CMS
Novartis Pharmaceuticals Corporation $3.8207/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602617 CMS
Novartis Pharmaceuticals Corporation $24.0107/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602589 CMS
Kyowa Kirin, Inc. $26.0107/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852982041 CMS
EMD Serono, Inc. $23.1907/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849200481 CMS
Janssen Pharmaceuticals, Inc $14.7207/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787806027 CMS
Novartis Pharmaceuticals Corporation $9.9207/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602613 CMS
CSL Behring $19.4807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820294569 CMS
Biogen, Inc. $23.8507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825579 CMS
GENZYME CORPORATION $18.5407/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843494433 CMS
Horizon Therapeutics plc $24.6107/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797073815 CMS
Celgene Corporation $11.7907/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783727097 CMS
AbbVie Inc. $17.4907/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794003259 CMS
Genentech USA, Inc. $24.3607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835888983 CMS
Amgen Inc. $14.6207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825147415 CMS
EMD Serono, Inc. $21.1506/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849195661 CMS
Neurocrine Biosciences, Inc. $124.9906/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837782439 CMS
Biohaven Pharmaceuticals, Inc. $22.2006/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852419109 CMS
Supernus Pharmaceuticals, Inc. $22.3506/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845004259 CMS
MDD US Operations, LLC $21.0706/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853054637 CMS
ACADIA Pharmaceuticals Inc $14.2906/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837990205 CMS
Novartis Pharmaceuticals Corporation $1,064.0006/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602581 CMS
Biogen, Inc. $1,152.0006/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827825573 CMS
Teva Pharmaceuticals USA, Inc. $34.6106/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839424441 CMS
Teva Pharmaceuticals USA, Inc. $14.1706/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839424439 CMS
Novartis Pharmaceuticals Corporation $2.7406/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602609 CMS
Novartis Pharmaceuticals Corporation $20.2106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812602611 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $381,663.19 497
PY2020 $178,464.79 327
PY2021 $142,969.68 289
PY2022 $275,724.54 388
PY2023 $283,904.68 392
PY2024 $199,482.42 356
PY2025 $265,329.17 506

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,250.00 1
PY2025 Principal investigator $2,069,908.54 76
PY2024 Principal investigator $2,579,584.93 69
PY2023 Principal investigator $2,234,674.74 63
PY2022 Recipient $1,250.00 1
PY2022 Principal investigator $1,461,797.17 46
PY2021 Recipient $3,063.64 4
PY2021 Principal investigator $1,009,346.62 44
PY2020 Recipient $3,371.57 16
PY2020 Principal investigator $450,281.10 33
PY2019 Recipient $7,055.67 25
PY2019 Principal investigator $756,298.77 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $260.00 12/18/2025 Non-covered Recipient Entity
Lone Star Neuro Of San Antonio
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1235996185
Principal investigator 1 Genentech, Inc. $9,334.80 12/10/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211621196
Principal investigator 1 Genentech, Inc. $9,856.00 12/04/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211621224
Principal investigator 1 Genentech, Inc. $821.00 12/01/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211621199
Principal investigator 1 Novartis Pharmaceuticals Corporation $20.00 12/01/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF SAN ANTONIO
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190303075
Principal investigator 1 GENZYME CORPORATION $17,794.80 11/17/2025 Non-covered Recipient Entity
Sheth Md Pa Lone Star Neurology Of San Antonio
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226157755
Principal investigator 1 GENZYME CORPORATION $12,004.20 11/17/2025 Non-covered Recipient Entity
Sheth Md Pa Lone Star Neurology Of San Antonio
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226157759
Principal investigator 1 TG Therapeutics, Inc. $8,850.00 11/10/2025 Non-covered Recipient Entity
Neurology Center of San Antonio
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197895
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,354.91 10/08/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF SAN ANTONIO
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190303071
Principal investigator 1 TG Therapeutics, Inc. $3,000.00 09/30/2025 Non-covered Recipient Entity
Neurology Center of San Antonio
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197877
Principal investigator 1 GENZYME CORPORATION $35,806.50 09/29/2025 Non-covered Recipient Entity
Sheth Md Pa Lone Star Neurology Of San Antonio
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226157752
Principal investigator 1 Genentech, Inc. $4,912.00 09/19/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211621212
Principal investigator 1 Genentech, Inc. $19,255.00 09/18/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211621216
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 09/15/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621132
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 09/15/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621135
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 09/15/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621151
Principal investigator 1 F. Hoffmann-La Roche AG $2,674.00 09/15/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621155
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 09/15/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621160
Principal investigator 1 Genentech, Inc. $24,290.30 09/08/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211621182
Principal investigator 1 TG Therapeutics, Inc. $1,500.00 08/31/2025 Non-covered Recipient Entity
Neurology Center of San Antonio
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197875
Principal investigator 1 Genentech, Inc. $10,350.00 08/15/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211621220
Principal investigator 1 GENZYME CORPORATION $23,459.40 08/04/2025 Non-covered Recipient Entity
Sheth Md Pa Lone Star Neurology Of San Antonio
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226157746
Principal investigator 1 GENZYME CORPORATION $13,177.35 07/28/2025 Non-covered Recipient Entity
Sheth Md Pa Lone Star Neurology Of San Antonio
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226157742
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 07/23/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621128
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621141
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 07/23/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621146
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 07/23/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621164
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 07/23/2025 Non-covered Recipient Entity
Neurology Center of San Antonio
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197881
Principal investigator 1 Genentech, Inc. $31,651.00 07/11/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211621177
Principal investigator 1 Genentech, Inc. $1,642.00 07/11/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211621187
Principal investigator 1 Genentech, Inc. $821.00 07/11/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211621193
Principal investigator 1 GENZYME CORPORATION $10,282.05 07/02/2025 Non-covered Recipient Entity
Sheth Md Pa Lone Star Neurology Of San Antonio
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226157725
Principal investigator 1 Genentech, Inc. $821.00 06/26/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211621173
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 06/20/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621087
Principal investigator 1 F. Hoffmann-La Roche AG $4,340.00 06/20/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621107
Principal investigator 1 Genentech, Inc. $24,176.00 06/03/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211621202
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 05/27/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621094
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 05/27/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621115
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 05/27/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621119
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 04/25/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621091
Principal investigator 1 F. Hoffmann-La Roche AG $1,139.00 04/25/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621097
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 04/25/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621102
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 04/25/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621110
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 04/25/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621124
Principal investigator 1 Genentech, Inc. $36,296.00 04/15/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211621207
Principal investigator 1 Genentech, Inc. $821.00 04/11/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211621169
Principal investigator 1 Celgene Corporation $190,657.00 03/31/2025 Non-covered Recipient Entity
Lone Star Neuro Of San Antonio
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222307145
Principal investigator 1 TG Therapeutics, Inc. $1,601.16 03/19/2025 Non-covered Recipient Entity
Neurology Center of San Antonio
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226197851
Principal investigator 1 GENZYME CORPORATION $5,897.10 03/17/2025 Non-covered Recipient Entity
Sheth Md Pa Lone Star Neurology Of San Antonio
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226157691
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,943.56 02/20/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190313657
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 02/19/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621014
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 02/19/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621024
Principal investigator 1 F. Hoffmann-La Roche AG $4,340.00 02/19/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621078
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 02/19/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621084
Recipient GENZYME CORPORATION $1,250.00 02/11/2025 Covered Recipient Physician A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) No dispute reported 06/30/2026 1226110439
Principal investigator 1 Novartis Pharmaceuticals Corporation $127,847.98 01/31/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF SAN ANTONIO
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190303073
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,795.40 01/28/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190313659
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621008
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621011
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621020
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621028
Principal investigator 1 F. Hoffmann-La Roche AG $1,228.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621032
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621037
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621041
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621046
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621049
Principal investigator 1 F. Hoffmann-La Roche AG $684.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621052
Principal investigator 1 F. Hoffmann-La Roche AG $2,430.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621056
Principal investigator 1 F. Hoffmann-La Roche AG $5,788.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621060
Principal investigator 1 F. Hoffmann-La Roche AG $1,228.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621063
Principal investigator 1 F. Hoffmann-La Roche AG $223.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621067
Principal investigator 1 F. Hoffmann-La Roche AG $5,624.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621071
Principal investigator 1 F. Hoffmann-La Roche AG $4,340.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621075
Principal investigator 1 F. Hoffmann-La Roche AG $2,594.00 01/22/2025 Non-covered Recipient Entity
LONE STAR NEUROLOGY OF SAN ANTONIO
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211621081
Principal investigator 1 Novartis Pharmaceuticals Corporation $260,398.87 01/07/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF SAN ANTONIO
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190303079
Principal investigator 1 GENZYME CORPORATION $2,049.30 01/06/2025 Non-covered Recipient Entity
Sheth Md Pa Lone Star Neurology Of San Antonio
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226157707
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,026,507.54 01/01/2025 Non-covered Recipient Entity
NEUROLOGY CENTER OF SAN ANTONIO
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190303077